Hair Loss Drugs Are Being Called the Next Ozempic. Investors Are Already Placing Their Bets
After GLP-1 weight-loss drugs turned obesity treatment into one of the most valuable consumer-health markets in decades, Wall Street has started hunting for the next condition that is extremely common, poorly treated, and something people will pay for themselves. Hair loss is now the leading candidate.
The comparison is commercial, not medical. Ozempic, Wegovy, Mounjaro and Zepbound succeeded because they worked better than older options, could be marketed directly to patients, and tapped a desire people already felt. Pattern baldness sits in a similar spot. It affects an estimated 50 million men and 30 million women in the United States alone. Transplants already send patients across borders. Telehealth firms already ship finasteride and low-dose oral minoxidil by mail. A better pill, cream or occasional injection would not have to create demand. It would only have to capture it.
What makes the moment unusual is how long the science stalled. Topical minoxidil won U.S. approval in 1988. Oral finasteride followed in 1997. For nearly 30 years, those two drugs were the entire approved toolkit for androgenetic alopecia, the most common form of hair loss. Everything else — shampoos, supplements, lasers, platelet-rich plasma, “natural DHT blockers” — sat around that core. Dermatologists still use those two medicines because they work for many people. They also plateau, require daily use, and come with side effects that push a large share of patients off treatment.
That drought is ending. A cluster of late-stage programs has sent related stocks soaring. Veradermics, which trades as MANE, has risen nearly 500 percent since its February IPO. Absci has more than doubled in 2026. Cosmo Pharmaceuticals has positive Phase 3 data for a topical male-pattern treatment and is preparing a U.S. filing. Analysts now talk about hair-loss drugs the way they talked about GLP-1s a few years ago: huge prevalence, limited options, and consumers already willing to spend.
Why the Ozempic analogy keeps sticking
The analogy has limits, and they matter. Obesity is a medical condition with cardiovascular and metabolic consequences. That helped GLP-1 drugs win insurance coverage as well as celebrity attention. Baldness is not a health crisis. Most of the new hair-loss drugs will likely be cash-pay products. That can still support large revenues if prices are high and people stay on therapy for years — which hair-loss treatment almost always requires. Stop the drug and the follicle usually shrinks again.
There is a second, awkward link. Semaglutide and tirzepatide have been associated with hair shedding in some users. A 10-year review of FDA adverse-event data found statistically significant alopecia signals for those two drugs, and not for several older GLP-1 medicines. Dermatologists generally describe the typical pattern as telogen effluvium: rapid weight loss and metabolic stress push more follicles into a resting phase. The shedding is often temporary. It is also visible, distressing, and already lifting demand for scalp serums, supplements and clinic visits. In that sense, weight-loss drugs have enlarged the market that hair-loss drugs hope to serve.
Jefferies has estimated that Cosmo’s male hair-loss therapy could reach $3 billion in global sales if the company finds a strong commercial partner. Needham analyst Gil Blum put the consumer psychology more bluntly: people already fly to Turkey to have hair moved around on their heads. A drug that avoided surgery would not need much explanation.
The three approaches closest to pharmacies
The pipeline is not one miracle molecule. It is three different bets.
Clascoterone 5 percent, from Cosmo, is a topical androgen-receptor blocker. Finasteride lowers DHT throughout the body. Clascoterone tries to block the hormone at the follicle, which is why developers argue it may avoid the sexual side effects that make some men quit Propecia. The Phase 3 SCALP 1 and SCALP 2 trials enrolled 1,465 men in the United States and Europe, the largest late-stage program ever run for a topical pattern-hair-loss drug. Cosmo reported a 539 percent relative improvement in target-area hair count versus placebo in SCALP 1 and 168 percent in SCALP 2. A year-long extension found that men who stayed on the drug kept gaining, while those who stopped lost coverage. That is the same maintenance problem every current treatment has. Cosmo has said it plans a U.S. new-drug application in the first quarter of 2027. If approved, clascoterone would be the first new approved mechanism for male pattern baldness in more than 30 years.
VDPHL01, from Veradermics, is an extended-release oral minoxidil tablet built for both men and women. Immediate-release oral minoxidil is already prescribed off-label, and many dermatologists consider it more convenient than foam or liquid. The problem is peak blood levels and heart-related side effects such as palpitations. Veradermics designed a slower-release pill to keep the hair-growth benefit while flattening those peaks. Phase 2/3 Study 302, with results released in April 2026, met its primary and key secondary endpoints. Company figures said 79 to 86 percent of participants reported improvement, versus 36 percent on placebo. A men’s Phase 3 trial is due later in 2026. A women’s Phase 3 study is recruiting. If regulators agree, VDPHL01 could become the first oral hair-loss pill specifically approved for women. That gap is commercially important. Women have fewer approved options, and they are a large share of the cash-pay market.
PP405, also known as suvomipic, is the most scientifically different candidate. Pelage Pharmaceuticals developed it as a topical inhibitor of the mitochondrial pyruvate carrier. The claim is that it reactivates dormant hair-follicle stem cells rather than blocking hormones or increasing blood flow. In a Phase 2a trial of 78 people, the drug was well tolerated and showed no systemic absorption. Among men with more advanced loss, 31 percent had a greater than 20 percent increase in hair density at eight weeks after only four weeks of treatment. Nobody in the placebo group hit that mark. Pelage has said some of the new hair was thick terminal hair in areas that previously looked bare. Independent critics have urged caution. The efficacy signal came from a small, short study and a subset of patients. Phase 3 was planned for 2026. The drug is not for sale. Gray-market versions advertised online are not the clinical product.
Absci is earlier still. Its ABS-201 program is an AI-designed injectable that could theoretically be given every several months. That format matters because GLP-1s have already trained millions of people to accept shots for an aesthetic goal.
What still works today
None of this replaces current care. Topical minoxidil remains the only widely available option for both sexes. Oral finasteride is still the most proven medical treatment for male pattern hair loss. Low-dose oral minoxidil is increasingly common off-label. JAK inhibitors such as baricitinib and ritlecitinib treat alopecia areata, an autoimmune disease, not ordinary pattern baldness. A transplant remains the only way to permanently move hair into a fully bald patch.
The honest clinical picture is less exciting than the stock chart. Existing drugs help many people if they start early and stay consistent. They do less once follicles have miniaturized for years. They do not work for everyone. They do not grow a full head of hair on a shiny scalp. Any new product will face the same test: visible hair, years of safety data, and a routine simple enough that people actually use it.
When anything actually arrives
Realistic launch windows start in late 2027, not this year. Clascoterone and VDPHL01 are furthest along. PP405 is behind them. Share prices have already priced in a lot of success. Cosmo’s Swiss-listed stock has lagged some U.S. peers even after positive data, a reminder that trial wins and commercial wins are different things.
For patients, the takeaway is narrower than the market story. If hair is thinning now, the evidence-based path is still a diagnosis first — pattern loss, telogen effluvium, thyroid disease, iron deficiency, autoimmune alopecia and medication effects are not the same problem — then minoxidil, a 5-alpha-reductase inhibitor if you are a man and can tolerate it, and a dermatologist who will say when a transplant is the better spend. Waiting for “the next Ozempic” is a reasonable investment thesis. It is a weak treatment plan. The drugs that change the category will have to grow hair people can see in a mirror, not just hair counts on a trial spreadsheet.
About The Author
